Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations

Thorax

Volumn 72, Issue 2, 2017, Pages 117-121

  Scioscia, Giulia ^a,b   Blanco, Isabel ^a,c,d   Arismendi, Ebymar ^a,c   Burgos, Felip ^a,c,d   Gistau, Concepción ^a   Foschino Barbaro, Maria Pia ^b   Celli, Bartolome ^e   O'Donnell, Denis E ^f   Agustí, Alvar ^a,c,d  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF FOGGIA   (Italy)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREATHING RATE; CARBON DIOXIDE BREATHING; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; FEMALE; FORCED VITAL CAPACITY; HUMAN; HYPERCAPNIA; LUNG GAS EXCHANGE; MALE; MAXIMAL EXPIRATORY PRESSURE; MAXIMAL INSPIRATORY PRESSURE; OBSERVATIONAL STUDY; PERCEPTION; SMOKING; TIDAL VOLUME; CLINICAL TRIAL; DISEASE COURSE; EPIDEMIOLOGY; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PILOT STUDY; PROSPECTIVE STUDY;

AGED; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DYSPNEA; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SMOKING;

EID: 84984971154     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-208332     Document Type: Article

References (27)

1. Vestbo J, Hurd SS, Agustí A, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
2. Celli BR, Decramer M, Wedzicha JA, et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir J 2015;45:879-905.
3. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-38.
4. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117(Suppl 2):398S-401S.
5. Scioscia G, Blanco I, Burgos F, et al. Breathlessness perception in COPD: Relationship with Exacerbation Frequency. Am J Respir Crit Care Med 2015;191: A2535.
6. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
7. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005;26:511-22.
8. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720-35.
9. Roca J, Burgos F, Sunyer J, et al. References values for forced spirometry. Group of the European Community Respiratory Health Survey. Eur Respir J 1998;11:1354-62.
10. Roca J, Burgos F, Barberà JA, et al. Prediction equations for plethysmographic lung volumes. Respir Med 1998;92:454-60.
11. Roca J, Rodriguez-Roisin R, Cobo E, et al. Single-breath carbon monoxide diffusing capacity (DLCO) prediction equations for a Mediterranean population. Am Rev Respir Dis 1990;141:1026-32.
12. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002;166:518-624.
13. Duffin J. Measuring the respiratory chemoreflexes in humans. Respir Physiol Neurobiol 2011;177:71-9.
14. Clausen JL. Pulmonary function testing. Guidelines and controversies. Equipment, methods and normal values. 1st edn. Orlando: Grune & Stratton, Inc., 1984:1-338.
15. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-81.
16. Marin JM, Montes de OM, Rassulo J, et al. Ventilatory drive at rest and perception of exertional dyspnea in severe COPD. Chest 1999;115:1293-300.
17. Altose MD, McCauley WC, Kelsen SG, et al. Effects of hypercapnia and inspiratory flow-resistive loading on respiratory activity in chronic airways obstruction. J Clin Invest 1977;59:500-7.
18. Montes de Oca M, Celli BR. Mouth occlusion pressure, CO2 response and hypercapnia in severe chronic obstructive pulmonary disease. Eur Respir J 1998;12:666-71.
19. O'Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997;155:109-15.
20. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society Statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012;185:435-52.
21. Laviolette L, Laveneziana P. Dyspnoea: a multidimensional and multidisciplinary approach. Eur Respir J 2014;43:1750-62.
22. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1608-13.
23. Laforest L, El Hasnaoui A, Pribil C, et al. Asthma patients' perception of their ability to influence disease control and management. Ann Allergy Asthma Immunol 2009;102:378-84.
24. Davis SQ, Permutt Z, Permutt S, et al. Perception of airflow obstruction in patients hospitalized for acute asthma. Ann Allergy Asthma Immunol 2009;102:455-61.
25. Herigstad M, Hayen A, Evans E, et al. Dyspnea-related cues engage the prefrontal cortex: evidence from functional brain imaging in COPD. Chest 2015;148:953-61.
26. Yu L, De Mazancourt M, Hess A, et al. Functional connectivity and information flow of the respiratory neural network in chronic obstructive pulmonary disease. Hum Brain Mapp 2016;37:2736-54.
27. Gifford AH, Mahler DA, Waterman LA, et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD 2011;8:160-1